Unlocking the Potential of Stem Cells: A New Frontier in Cancer Immunotherapy

Author: ScaleReady

Cancer immunotherapy has revolutionized treatment, but existing strategies have limitations. Natural Killer (NK) cells, part of our immune system, show amazing potential to destroy both blood and solid tumor cancers. However, getting enough consistently potent NK cells for therapy is tricky.


A New Source of Killer Cells
Researchers are turning to induced pluripotent stem cells (iPSCs). These stem cells can become almost any cell type, offering a potentially unlimited supply of NK cells. But current methods to make NK cells from iPSCs are unreliable, use animal products (risky for patients), or don’t make enough cells.


A Better Way to Make NK Cells
A new study changes the game! Scientists have developed a way to reliably create large amounts of NK cells from iPSCs without animal products by focusing on an intermediate step. First, they carefully guide iPSCs into becoming the precursors of blood cells (CD34+ hematopoietic stem cells), and only then transforming these into NK cells.


Impressive Results

This new technique is a major breakthrough:

  • Purity: Over 95% of cells become true NK cells
  • Yield: A single iPSC can make 500 NK cells – that’s huge!
  • Potency: These iPSC-derived NK cells killed over 90% of test cancer cells!


The Future of Cancer Immunotherapy

This optimized process means safe, consistent supplies of incredibly powerful NK cells for off-the-shelf cancer treatments. This could change the lives of countless patients, offering new hope in the fight against this devastating disease.

Related Blogs

Multiply Labs and Wilson Wolf Join Forces to Automate Cell Therapy Manufacturing with G-Rex® Bioreactors

Multiply Labs and Wilson Wolf are partnering to automate G-Rex® bioreactors for cheaper, more accessible cell therapy manufacturing. This partnership focuses on automating Wilson Wolf's innovative G-Rex® bioreactors, aiming to revolutionize CGT manufacturing.

Innovating Cell Therapy Manufacturing: The Path to Decentralization and GMP Success

Cell therapies are exploding with potential, offering groundbreaking new treatments for a wide range of diseases. Yet, a central challenge lies in bringing these complex therapies out of the lab and into the real world. In a recent panel discussion, Josh Ludwig (Global Commercial Director, ScaleReady) and Stuart Curbishley (Chief Manufacturing & Development Officer, Adthera Bio) shed light on this complex transition.

Advancing Immune Cell Therapies Through Efficient Cell Culture Techniques

In an expert roundtable discussion by Cell and Gene Therapy Insights, the potential of cell culture in immune cell therapies takes center stage, offering promising possibilities for the future of regenerative medicine.

Josh Ludwig Discusses Innovative Approaches to Cell & Gene Therapy Manufacturing in Medical Alley Podcast

In an enlightening episode of the Medical Alley Podcast, Josh Ludwig, the Global Director of Commercial Operations at ScaleReady, shares invaluable insights into the world of cell and gene therapy manufacturing.

Josh Ludwig Shares Vision for Streamlined Cell and Gene Therapy with Medical Alley

In an interview published by Medical Alley, Josh Ludwig, the Global Director of Commercial Operations at ScaleReady, discussed ScaleReady's innovative approach to revolutionizing the cell and gene therapy industry.

Josh Ludwig Shares Insights on Achieving Scalable and Cost-Effective Cell and Gene Therapy Manufacturing

This interview provides valuable insights into Ludwig's vision for the future of CGT manufacturing, focusing on creating a robust and accessible platform that empowers the industry to deliver life-changing therapies to patients worldwide.

Early Adoption and Partnerships — The Secret to Commercialization Success in Regenerative Medicine

The power of collaborative partnerships is highlighted as a game-changer in driving commercialization efforts. By leveraging the expertise of multiple stakeholders, including researchers, clinicians and industry players, cell and gene therapy manufacturers can navigate complex challenges and accelerate the delivery of groundbreaking therapies to patients.

Simplifying Processes and Prioritizing Standardization: A Better Approach to Scaling Cell and Gene Therapies

The road to scaling cell and gene therapies successfully lies in prioritizing simplicity and standardization. By addressing complexity first and then implementing automation strategically, the industry can bring life-changing treatments to more patients worldwide.

Josh Ludwig Discusses Key Themes at ISCT 2023 Paris Meeting

The future of cell and gene therapy manufacturing is poised for transformative advancements, driven by key themes that aim to enhance scalability, efficiency, and safety. One crucial theme is automation and process standardization.

Josh Ludwig Joins Industry Experts in Roundtable Discussion: Redefining Manufacturing

Josh Ludwig discusses the need to redefine manufacturing to better treat more patients with various modalities around the world and meet the growing demand of the treatments during Medicine Maker panel.

Shaping the Future of Cell and Gene Therapy Manufacturing: Key Trends and Innovations

Understand insights into the key trends that are redefining manufacturing processes in the rapidly evolving sector of CGT as discussed at the recent ISCT 2023 Annual Meeting.

Are you ready to scale?

Let’s talk more about how ScaleReady can advance your cell and gene therapy research and manufacturing with ingenious efficiency.
ScaleReady Logo Careers

Meet the Author